AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2248531
Drug: Amoxycillin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (25 mg/kg/day) plus cimetidine for six weeks
Trial: 23255270
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no joint infusion)
Trial: 11069509
Drug: 5%, 10%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5%, 10%, and 25% dilutions of FP cream under wet wrap
Trial: 11069509
Drug: 0%, 5%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0%, 5%, 10%, and 25% dilutions of FP cream applied on the whole body under wet wrap
Trial: 6425893
Drug: Phospholipid liposomes
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phospholipid liposomes (PL) 250 mg IV bolus plus additional 250 mg infused IV over 60 minutes
Trial: 29843492
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg daily clopidogrel
Trial: 27388980
Drug: Intraoperative sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative sufentanil (0.25 μg × kg−1 bolus, 0.15 μg × kg−1, repetition after 60 min)
Trial: 23583011
Drug: Lurasidone (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40-160 mg/day)
Trial: 23583011
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (200-800 mg/day)
Trial: 17713342
Drug: 20% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% sucrose solution
Trial: 11052580
Drug: Tailored FEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored FEC regimen with G-CSF support (n=251)
Trial: 1739192
Drug: Generic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic albuterol MDI (2 puffs, 180 micrograms)
Trial: 28609389
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.625 mg/bazedoxifene 20 mg
Trial: 28609389
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.45 mg/bazedoxifene 20 mg
Trial: 21292793
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide as a slow intravenous infusion over 15 min plus placebo (SIG)
Trial: 21292793
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide as an intravenous bolus infusion over 2 min plus placebo (BIG)
Trial: 8697059
Drug: Forskolin ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forskolin ointment, applied 5 times a week for 4 weeks, with diet and walking
Trial: 8697059
Drug: Yohimbine ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine ointment, applied 5 times a week for 4 weeks, with diet and walking
Trial: 8697059
Drug: Aminophylline ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline ointment, 10%, applied 5 times a week for 6 weeks, with diet and walking
Trial: 26340658
Drug: Nebulised tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised tobramycin (300 mg twice daily for 3 months)
Trial: 23879671
Drug: Azithromycin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1500 mg/week for four weeks)
Trial: 15541405
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of levonorgestrel (LNG)
Trial: 15541405
Drug: Single 0.75-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 0.75-mg dose of levonorgestrel (half dose)
Trial: 2564505
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline ethylenediamine (aminophylline), 7 mg/kg
Trial: 2564505
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of theophylline (375 mg)
Trial: 2564505
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of theophylline ethylenediamine
Trial: 31593088
Drug: Bronchial blockers
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchial blockers (BB)
Trial: 30716942
Drug: Synbiotic group
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic group (SG): 40 g of extruded sorghum plus 100 mL of unfermented probiotic milk
Trial: 17419259
Drug: Placebo (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (continuous infusion for 48 hours)
Trial: 15266769
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of meloxicam (Group M, n = 27)
Trial: 11504270
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral [14C]omapatrilat
Trial: 28159194
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg
Trial: 29453687
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg
Trial: 24725355
Drug: Condoms plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condoms plus emergency contraception pills (ECP) (Levonorgestrel)
Trial: 24698485
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg once daily
Trial: 25944344
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily
Trial: 12686241
Drug: Expensive combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expensive combination (sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) and BSS Plus)
Trial: 9370845
Drug: Cisatracurium 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.20 mg.kg‐1
Trial: 2885187
Drug: nalbuphine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.2 mg/kg
Trial: 2885187
Drug: morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.2 mg/kg
Trial: 31062377
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of mother's milk (0.2 mL of mother's colostrum or milk prior to gavage feeding)
Trial: 31062377
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of mother's milk
Trial: 27488326
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (ST)
Trial: 23107871
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral 150 mg of vismodegib for 7 days
Trial: 23107871
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg of moxifloxacin
Trial: 8923359
Drug: sCT 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCT 100 IU/day and calcium (Ca) 500 mg/day
Trial: 3535473
Drug: Diltiazem therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem therapy for 14 days
Trial: 15960558
Drug: Second-generation antidepressants
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antidepressants (primarily fluoxetine, duration 6 to 12 weeks)
Trial: 15960558
Drug: First-generation antidepressants
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antidepressants (including placebo, phenelzine, and imipramine, N = 420)
Trial: 10338172
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg morphine + 30 mg ketorolac (group KM)
Trial: 10338172
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac (group K30)
Trial: 10338172
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ketorolac (group K60)
Trial: 1938398
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (phase-adapted therapy using diverse topical modalities)
Trial: 6996897
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg intravenously)
Trial: 26497535
Drug: Mindfulness-Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Therapy (MBT)
Trial: 30222962
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid treatment
Trial: 30222962
Drug: Baseline triglyceride
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline triglyceride level ≤ 154 mg/dL
Trial: 30222962
Drug: Baseline aspartate
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline aspartate aminotransferase level ≤ 49 U/L
Trial: 30222962
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in alanine aminotransferase level at week 24 by 17 U/L or more
Trial: 22760341
Drug: 3-day combined
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day combined clavulanate/amoxicillin preparation
Trial: 22760341
Drug: 10-day amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-day amoxicillin treatment
Trial: 15001195
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg twice daily) + diet
Trial: 9695299
Drug: Budesonide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (200 micrograms, twice a day for 3 weeks)
Trial: 9695299
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (2 mg, twice a day for 3 weeks)
Trial: 9695299
Drug: Salmeterol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (25 micrograms, twice a day for 3 weeks)
Trial: 2809777
Drug: 100-g carbohydrate
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-g carbohydrate meal
Trial: 2809777
Drug: 50-g glucose
RxNorm normalized name: glucose 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-g glucose load (Glucola)
Trial: 342621
Drug: Trivalent vaccine
RxNorm normalized name: Fluzone 2024-2025 trivalent vaccine Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent vaccine (A/New Jersey/76, A/Victoria/75, B/Hong Kong/73)
Trial: 25990482
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg misoprostol sublingually
Trial: 12753338
Drug: Reinforced group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforced group (n = 114) received IFN-2b 6 million units (MU) thrice weekly (TIW) and ribavirin for 48 weeks
Trial: 9354208
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide dinitrate b.d.
Trial: 9354208
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg isosorbide dinitrate b.d.
Trial: 2873440
Drug: Inhaled platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled platelet activating factor (PAF)
Trial: 31802559
Drug: Curcumin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1,500 mg/day)
Trial: 20438830
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-teratogenic agents)
Trial: 15735614
Drug: BIBN4096BS (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBN4096BS (2.5 mg)
Trial: 1353996
Drug: Cetirizine (CTZ)
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine (CTZ) 10 mg once a day for 3 weeks
Trial: 1353996
Drug: Terfenadine (TER)
DrugBank: Terfenadine (DB00342)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terfenadine (TER) 60 mg b.i.d. for 3 weeks
Trial: 6407047
Drug: Fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl citrate (0.1 mg)
Trial: 6407047
Drug: Naloxone (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.2 or 0.4 mg)
Trial: 28957983
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy intervention (modified constraint-induced movement therapy) for 3 hours for 10 consecutive days
Trial: 28957983
Drug: Individual modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual modified constraint-induced movement therapy for 3 hours for 10 consecutive days
Trial: 20590736
Drug: Voglibose 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 0.2 mg thrice daily
Trial: 24843649
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg once daily
Trial: 16270633
Drug: Dexamethasone 1.0
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL / DEXAMETHASONE 1.0 mg in 1 mL OPHTHALMIC SUSPENSION/ DROPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1.0 mg/kg b.i.d on two days
Trial: 10635302
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (UFT less than 300 mg/day, 5 days a week, and/or 5‐FU less than 440 mg/m2/24 hr once a week)
Trial: 7772361
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg intravenous (i.v.) ondansetron
Trial: 7772361
Drug: 0.075 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg/kg i.v. droperidol
Trial: 2373131
Drug: Metoprolol CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR 50 mg
Trial: 22673961
Drug: Monthly practice
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly practice of CPR skills
Trial: 16952675
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg alfuzosin daily
Trial: 8178408
Drug: KLH (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLH (1 mg intracutaneously, followed by 30 mg weekly for 6 weeks and then monthly for 1 year)
Trial: 30466622
Drug: A. afra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A. afra tea infusion (1l/d of dry leaf/twig tea infusions divided into 3 aliquots daily for 7 days)
Trial: 30466622
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) treatment (followed manufacturer posology)
Trial: 30466622
Drug: PZQ and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZQ and A. afra treatment in females
Trial: 30466622
Drug: A. annua
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A. annua treatment
Trial: 12593999
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate monotherapy
Trial: 10330960
Drug: Antilymphocyte antibody
RxNorm normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilymphocyte antibody induction therapy
Trial: 10330960
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with cyclosporine, azathioprine, and prednisone
Trial: 2205078
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid treatment
Trial: 25043197
Drug: Peginterferon lambda-1a
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda-1a (Lambda) 120 μg
Trial: 25064437
Drug: Peginterferon lambda-1a
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda-1a (Lambda) 180 μg
Trial: 25064437
Drug: Peginterferon lambda-1a
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda-1a (Lambda) 240 μg
Trial: 19524176
Drug: Hypertensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertensive group pre-treatment
Trial: 17925066
Drug: Short-acting β2-agonist
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting β2-agonist (albuterol)
Trial: 17925066
Drug: Long-acting β2-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β2-agonists
Trial: 3132428
Drug: sustained-release buccal
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release buccal nitroglycerin (2.5 mg, given 8-hourly)
Trial: 29051184
Drug: Hydroxyurea (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (20 ± 2.5 mg/kg per day for 12 months)
Trial: 26475802
Drug: Crystalloid (Ringers‐acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid (Ringers‐acetate 20 ml kg(‐1), n=15)
Trial: 26475802
Drug: Colloid (Venofundin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid (Venofundin 10 ml kg(‐1), n=15)
Trial: 17192501
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet containing 15 mg of pioglitazone plus 850 mg metformin (fed state)
Trial: 17192501
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet (fed state)
Trial: 9727512
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dorzolamide and latanoprost
Trial: 28552240
Drug: Subcutaneous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous nitroglycerin plus diltiazem (drug treatment group)
Trial: 18226672
Drug: EAMD+OC (triphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAMD+OC (triphasic OC containing 180‐250 mcg norgestimate/25 mcg ethinyl estradiol)
Trial: 9324339
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, cytarabine, coordinated intrathecal chemotherapy)
Trial: 3027601
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (20 mg X 3)
Trial: 18936595
Drug: Occlusal splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal splint (OS) therapy
Trial: 21946400
Drug: Sham laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham laser therapy
Trial: 12842988
Drug: New prognostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New prognostic score based on median expression ratio after consolidation therapy and 75th percentile of expression ratio at diagnosis
Trial: 12842988
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of fusion gene expression at diagnosis or less than 3 logs of tumor reduction during the first 3 to 4 months of therapy
Trial: 8741364
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day calcium lactate for 10 months (control)
Trial: 1430999
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (beta-lactam and aminoglycoside)
Trial: 14582817
Drug: Diphenhydramine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine, 50 mg
Trial: 4008809
Drug: Cyproheptadine, 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine, 16 mg
Trial: 4008809
Drug: Hydroxyzine, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine, 75 mg per day for 3 weeks
Trial: 9862082
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg haloperidol
Trial: 989370
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg haloperidol
Trial: 12483184
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with streptokinase (250,000 units bolus followed by 100,000 units/hr, max 4,000,000 units)
Trial: 9891197
Drug: RW94 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RW94 (5 grams administered orally after each main meal)